Zarah van der Pal, Hilde M Geurts, Jonas M B Haslbeck, Alex van Keeken, Anne Marijn Bruijn, Linda Douw, Daan van Rooij, Barbara Franke, Jan Buitelaar, Nanda Lambregts-Rommelse, Catharina Hartman, Jaap Oosterlaan, Marjolein Luman, Liesbeth Reneman, Pieter J Hoekstra, Tessa F Blanken, Anouk Schrantee
{"title":"患有注意力缺陷/多动症的儿童、青少年和成人的兴奋剂药物治疗与症状之间的相互关系。","authors":"Zarah van der Pal, Hilde M Geurts, Jonas M B Haslbeck, Alex van Keeken, Anne Marijn Bruijn, Linda Douw, Daan van Rooij, Barbara Franke, Jan Buitelaar, Nanda Lambregts-Rommelse, Catharina Hartman, Jaap Oosterlaan, Marjolein Luman, Liesbeth Reneman, Pieter J Hoekstra, Tessa F Blanken, Anouk Schrantee","doi":"10.1007/s00787-024-02610-8","DOIUrl":null,"url":null,"abstract":"<p><p>Stimulant medication is effective in alleviating overall symptom severity of attention-deficit/hyperactivity disorder (ADHD), yet interindividual variability in treatment response and tolerability still exists. While network analysis has identified differences in ADHD symptom relations, the impact of stimulant medication remains unexplored. Increased understanding of this association could provide valuable insights for optimizing treatment approaches for individuals with ADHD. In this study, we compared and characterized ADHD symptom networks (including 18 ADHD symptoms) between stimulant-treated (n = 348) and untreated (n = 70) individuals with ADHD and non-ADHD controls (NACs; n = 444). Moreover, we compared symptom networks between subgroups defined by their stimulant treatment trajectory (early-and-intense use, late-and-moderate use). Stimulant-treated individuals with ADHD showed stronger associations between symptoms, compared with untreated individuals with ADHD and NACs. We found no differences in symptom networks between the stimulant treatment trajectory subgroups. Prospective longitudinal studies are needed to disentangle whether the identified differences stem from treatment or pre-existing factors.</p>","PeriodicalId":11856,"journal":{"name":"European Child & Adolescent Psychiatry","volume":" ","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Stimulant medication and symptom interrelations in children, adolescents and adults with attention-deficit/hyperactivity disorder.\",\"authors\":\"Zarah van der Pal, Hilde M Geurts, Jonas M B Haslbeck, Alex van Keeken, Anne Marijn Bruijn, Linda Douw, Daan van Rooij, Barbara Franke, Jan Buitelaar, Nanda Lambregts-Rommelse, Catharina Hartman, Jaap Oosterlaan, Marjolein Luman, Liesbeth Reneman, Pieter J Hoekstra, Tessa F Blanken, Anouk Schrantee\",\"doi\":\"10.1007/s00787-024-02610-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Stimulant medication is effective in alleviating overall symptom severity of attention-deficit/hyperactivity disorder (ADHD), yet interindividual variability in treatment response and tolerability still exists. While network analysis has identified differences in ADHD symptom relations, the impact of stimulant medication remains unexplored. Increased understanding of this association could provide valuable insights for optimizing treatment approaches for individuals with ADHD. In this study, we compared and characterized ADHD symptom networks (including 18 ADHD symptoms) between stimulant-treated (n = 348) and untreated (n = 70) individuals with ADHD and non-ADHD controls (NACs; n = 444). Moreover, we compared symptom networks between subgroups defined by their stimulant treatment trajectory (early-and-intense use, late-and-moderate use). Stimulant-treated individuals with ADHD showed stronger associations between symptoms, compared with untreated individuals with ADHD and NACs. We found no differences in symptom networks between the stimulant treatment trajectory subgroups. Prospective longitudinal studies are needed to disentangle whether the identified differences stem from treatment or pre-existing factors.</p>\",\"PeriodicalId\":11856,\"journal\":{\"name\":\"European Child & Adolescent Psychiatry\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2024-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Child & Adolescent Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00787-024-02610-8\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Child & Adolescent Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00787-024-02610-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
Stimulant medication and symptom interrelations in children, adolescents and adults with attention-deficit/hyperactivity disorder.
Stimulant medication is effective in alleviating overall symptom severity of attention-deficit/hyperactivity disorder (ADHD), yet interindividual variability in treatment response and tolerability still exists. While network analysis has identified differences in ADHD symptom relations, the impact of stimulant medication remains unexplored. Increased understanding of this association could provide valuable insights for optimizing treatment approaches for individuals with ADHD. In this study, we compared and characterized ADHD symptom networks (including 18 ADHD symptoms) between stimulant-treated (n = 348) and untreated (n = 70) individuals with ADHD and non-ADHD controls (NACs; n = 444). Moreover, we compared symptom networks between subgroups defined by their stimulant treatment trajectory (early-and-intense use, late-and-moderate use). Stimulant-treated individuals with ADHD showed stronger associations between symptoms, compared with untreated individuals with ADHD and NACs. We found no differences in symptom networks between the stimulant treatment trajectory subgroups. Prospective longitudinal studies are needed to disentangle whether the identified differences stem from treatment or pre-existing factors.
期刊介绍:
European Child and Adolescent Psychiatry is Europe''s only peer-reviewed journal entirely devoted to child and adolescent psychiatry. It aims to further a broad understanding of psychopathology in children and adolescents. Empirical research is its foundation, and clinical relevance is its hallmark.
European Child and Adolescent Psychiatry welcomes in particular papers covering neuropsychiatry, cognitive neuroscience, genetics, neuroimaging, pharmacology, and related fields of interest. Contributions are encouraged from all around the world.